Neuberger Berman Group
KYMR icon

Neuberger Berman Group’s Kymera Therapeutics KYMR Stock Holding History

Neuberger Berman Group’s Portfolio KYMR Stock Details KYMR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$5.92M Buy
71,116
+12,634
+22% +$1M ﹤0.01% 944
2025
Q4 		$4.55M Buy
+58,482
New +$3.95M ﹤0.01% 990
2024
Q4 		– Sell
-78,236
Closed -$3.7M – 1977
2024
Q3 		$3.7M Sell
78,236
-40,956
-34% -$1.81M ﹤0.01% 1004
2024
Q2 		$3.56M Sell
119,192
-5,987
-5% -$207K ﹤0.01% 982
2024
Q1 		$5.03M Buy
125,179
+4,100
+3% +$147K ﹤0.01% 922
2023
Q4 		$3.08M Buy
+121,079
New +$2.17M ﹤0.01% 1019

Other funds holding KYMR

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
AVLSA
Atlas Venture Life Science Advisors Cambridge, Massachusetts $790M AUM 223.66% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $3.61B AUM 203.3% 1-Year Est. Return

Neuberger Berman Group's KYMR Position: Q1 2026 in Review

Neuberger Berman Group increased its Kymera Therapeutics (KYMR) stake by 22% in Q1 2026, buying an estimated $1M and bringing the position to 71,116 shares worth $5.92M. The position accounts for ﹤0.01% of the portfolio, ranked #944.

Neuberger Berman Group first reported a position in KYMR in Q4 2023 and has held it in 6 quarters since. 256 funds tracked by Wall St. Rank hold KYMR as of Q1 2026.

  • Neuberger Berman Group held 71,116 shares of Kymera Therapeutics worth $5.92M as of Q1 2026.
  • Neuberger Berman Group bought 12,634 Kymera Therapeutics shares in Q1 2026, an estimated $1M.
  • Kymera Therapeutics made up ﹤0.01% of Neuberger Berman Group's portfolio in Q1 2026, its #944 holding.
  • Neuberger Berman Group first reported a position in Kymera Therapeutics in Q4 2023 and has held it in 6 quarters since.
  • 256 funds tracked by Wall St. Rank held Kymera Therapeutics as of Q1 2026.

Based on Neuberger Berman Group's 13F filing for Q1 2026, filed 14 May 2026.